Please login to the form below

Not currently logged in
Email:
Password:

enasidenib

This page shows the latest enasidenib news and features for those working in and with pharma, biotech and healthcare.

Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial

Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial

If approved, the CC-486 will round out an AML franchise at Celgene that along with Vidaza also includes Agios-partnered  Idhifa(enasidenib), a targeted second-line therapy for patients with

Latest news

  • Novartis gets EU nod for leukaemia drug Rydapt Novartis gets EU nod for leukaemia drug Rydapt

    or AML with myelodysplasia-related changes (AML-MRC) – while Celgene/Agios claimed approval for Idhifa (enasidenib) as a treatment for AML patients with the IDH2 mutation.

  • Celgene, Agios get FDA OK for leukaemia drug Idhifa Celgene, Agios get FDA OK for leukaemia drug Idhifa

    Idhifa ( enasidenib or AG-221) has been cleared for the treatment of relapsed or refractory acute myeloid leukaemia (AML) in patients with an IDH2 mutation, a group that accounts for somewhere ... At Celgene, enasidenib will slot into its blood cancer

  • Celgene bags US priority review for cancer metabolism drug Celgene bags US priority review for cancer metabolism drug

    First approval for enasidenib could be just six months away. Celgene could be just six months away from getting its first approval for enasidenib, a first-in-class drug for acute ... Celgene filed for approval of enasidenib as a treatment for relapsed,

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics